---
title: "Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positive"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295935616.md"
description: "Moleculin Biotech reported a Q2 2026 net loss of $7.6 million and held $7.3 million in cash, supplemented by a post-quarter $9.3 million raise funding operations into Q1 2027. Operationally, the company highlighted positive interim efficacy from its MIRACLE Phase 2/3 trial for Annamycin in relapsed/refractory AML, showing significantly higher complete remission rates than controls with no cardiotoxicity. Enrollment is on track for September 2026."
datetime: "2026-08-14T12:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295935616.md)
  - [en](https://longbridge.com/en/news/295935616.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295935616.md)
generator: "portal-rs"
---

# Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positive

Moleculin Biotech reported second-quarter 2026 results showing a net loss of $7.6 million for the three months ended June 30, 2026 and cash and cash equivalents of approximately $7.3 million as of quarter-end. The company said it raised an additional $9.3 million after quarter-end and expects cash to fund operations into Q1 2027. Operationally, Moleculin highlighted positive interim unblinded efficacy from the pivotal MIRACLE Phase 2/3 trial of Annamycin, with higher complete remission rates versus control and no evidence of cardiotoxicity.

**Financial Highlights**

-   Net loss (three months ended June 30, 2026): $7.635 million.
-   Net loss available to common stockholders (three months ended June 30, 2026): $7.964 million.
-   Six-month net loss (ended June 30, 2026): $20.480 million.
-   Research and development expense (Q2 2026): $5.450 million; General and administrative expense (Q2 2026): $2.103 million.
-   Cash and cash equivalents as of June 30, 2026: $7.262 million; subsequent financing proceeds: $9.3 million, which management expects to support operations into Q1 2027.

**Business Highlights**

-   Reported positive preliminary unblinded efficacy from the first 45 patients in Part A of the MIRACLE Phase 2/3 trial evaluating Annamycin plus cytarabine in relapsed/refractory AML; both Annamycin arms showed CR rates at least three times higher than control (43% and 36% vs. 12%).
-   Composite complete remission (CRc) in the interim cohort reached 50% and 57% in the two Annamycin cohorts versus 29% for control; interim population included substantial proportions of older patients and those with prior 1L regimens including 7+3 and venetoclax.
-   Enrollment in Part A progressing toward the planned 90-patient milestone expected in September 2026, with unblinded efficacy readout for Part A expected in the December 2026–February 2027 timeframe.
-   Company expects to select optimal Annamycin dose from Part A data and initiate Part B in the first half of 2027; Part B recruitment is targeted to complete in 2028 with primary efficacy readouts for 2nd line subjects in 2028 and rolling NDA submission to begin in 2028.
-   Annamycin continues to show a differentiated cardiac safety profile with no detectable cardiotoxicity reported and favorable investigator feedback and market research indicating strong physician intent to prescribe based on efficacy and transplant-bridging potential.

Original SEC Filing: Moleculin Biotech, Inc. \[ MBRX \] - 8-K - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech announces annual shareholder meeting](https://longbridge.com/en/news/296828733.md)
- [Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AML](https://longbridge.com/en/news/295935232.md)
- [ExpreS2ion says ES2B-C001 Phase I trial shows anti-HER2 antibody response in 12 of 13 patients, no dose-limiting toxicities](https://longbridge.com/en/news/296452642.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**